Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (459)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02323360 | A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC | terminated | N/A | 41 | Istituto Clinico HumanitasOTHER | 1 | Oct 25, 2019 | clinicaltrials |
| NCT02102971 | Observational Study of Biomarker During Liver Surgery | terminated | — | 41 | University of FloridaOTHER | 1 | Sep 25, 2019 | clinicaltrials |
| NCT02147301 |
| TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve |
| terminated |
| N/A |
| 17 |
| University of California, San FranciscoOTHER |
| 1 |
| Sep 10, 2019 |
| clinicaltrials |
| NCT01817205 | Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular Carcinoma | terminated | N/A | 8 | Chinese University of Hong KongOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01806740 | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC(DCE-MRI) | terminated | Phase 4 | 37 | GuerbetINDUSTRY | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01465464 | Orantinib In Combination With Transcatheter Arterial Chemoembolization In Patients With Unresectable Hepatocellular Carcinoma(ORIENTAL) | terminated | Phase 3 | 888 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 3 | Aug 7, 2019 | clinicaltrials |
| NCT03318562 | A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC | terminated | Phase 2 | 3 | Effector TherapeuticsINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | terminated | Phase 1 | 3 | Aeon Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT01408043 | Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma | terminated | N/A | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT01290523 | Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma | terminated | N/A | 14 | University of California, San FranciscoOTHER | 1 | May 13, 2019 | clinicaltrials |
| NCT01676194 | Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma(CATCH) | terminated | Phase 3 | 7 | Rennes University HospitalOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT02950025 | Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies | terminated | Phase 2 | 5 | Washington University School of MedicineOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 29 | Taiwan Liposome CompanyINDUSTRY | 2 | Feb 26, 2019 | clinicaltrials |
| NCT00465842 | Protein Biomarker in Hepatocellular Carcinoma | terminated | — | 211 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02748304 | Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma | terminated | N/A | 52 | Fudan UniversityOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT01600196 | Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus | terminated | Phase 4 | 126 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial | terminated | Phase 2 / Phase 3 | 79 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02787954 | Prospective Tumor Response Evaluation(Liver) | terminated | — | 10 | The University of Texas Health Science Center, HoustonOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT02254681 | Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC | terminated | Phase 2 | 6 | Allina Health SystemOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT02967523 | Surefire Precision Infusion System Registry | terminated | — | 111 | Surefire Medical, Inc.INDUSTRY | 1 | Sep 11, 2018 | clinicaltrials |
| NCT01425996 | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 3 | Taiwan Liposome CompanyINDUSTRY | 1 | Aug 21, 2018 | clinicaltrials |
| NCT02057874 | 3-Tesla MRI Response to TACE in HCC (Liver Cancer) | terminated | N/A | 2 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02748161 | DEB-TACE for Hepatocellular Carcinoma(QED) | terminated | N/A | 170 | Surefire Medical, Inc.INDUSTRY | 1 | Jun 21, 2018 | clinicaltrials |
| NCT02690350 | An Open Study Assessing the Safety and Tolerability of U3-1784 | terminated | Phase 1 | 10 | Daiichi SankyoINDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT01259024 | The LC Bead Trial; Transarterial Chemoembolization of Hepatocellular Carcinoma (HCC)With a Drug-eluting Bead | terminated | N/A | 1 | Washington University School of MedicineOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT00459108 | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT00878215 | Clinical Application of Image-Guided Liver Surgery | terminated | Phase 2 | 40 | Washington University School of MedicineOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | terminated | Phase 1 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00623077 | MT2004-30: Tomotherapy for Solid Tumors | terminated | Phase 1 | 23 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT02549755 | 11C-acetate for Treatment Response After Radiotherapy for HCC | terminated | Phase 2 | 1 | Justin SimsOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00003530 | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT01334710 | A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer | terminated | Phase 2 | 3 | Emory UniversityOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR) | terminated | Phase 2 | 3 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT02585687 | Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma(ETAFIRM) | terminated | N/A | 28 | Hospices Civils de LyonOTHER | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | terminated | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | terminated | Phase 2 | 24 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 41 | University of WashingtonOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | terminated | N/A | 5 | University of Alabama at BirminghamOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT00524316 | Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 16 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) | terminated | Phase 1 | 33 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | terminated | — | 117 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma | terminated | Phase 2 | 5 | Seoul National University HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | terminated | Phase 4 | 3 | Massachusetts General HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Oct 25, 2019source: clinicaltrials